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Total parenteral nutrition (TPN) administration in a mouse model leads to a local mucosal inflammatory response,
resulting in a loss of epithelial barrier function (EBF). Although, the underlying mechanisms are unknown, a
major contributing factor is a loss of growth factors and subsequent critical downstream signaling. An important
component of these is the p-Akt pathway. An additional contributing factor to the loss of EBF with TPN is an
increase in proinflammatory cytokine abundance within the mucosal epithelium, including TNF-α and IFN-γ. Loss
of critical nutrients, including glutamine and glutamate, may affect EBF, contributing to the loss of tight junction
proteins. Finding protective modalities for the small intestine during TPN administration may have important
clinical applications. Supplemental glutamine and glutamate may be examples of such agents.
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Introduction
Parenteral nutrition (PN) is commonly used as
treatment for many patients, ranging from short-
term use in patients with gastrointestinal dysfunc-
tion,1 to long-term use in patients with short bowel
syndrome.2,3 Although it is lifesaving for many, PN
use is associated with numerous complications, in-
cluding an increase in systemic infections, includ-
ing pneumonia as well as infections of the uri-
nary tract and surgical wounds.4,5 Although the
precise etiology of this increased rate of infec-
tions has not been fully established, it is known
that organisms arising from enteric flora consti-
tute a large percent of these infections. This sug-
gests that a major loss of epithelial barrier func-
tion (EBF) could be a contributing factor leading
to this increase in infectious complications. Addi-
tional contributing factors include a loss of local
growth factors and increase in several proinflam-
matory mucosal cytokines. This review summarizes
the work done by our laboratory and others on
total parenteral nutrition (TPN)-associated loss of
EBF.
TPN administration results in a
proinflammatory cytokine state
within the intestinal mucosa
The development of these inflammatory changes is
complex and leads to atrophy of small bowel villi, an
increase in epithelial cell (EC) apoptosis,6,7 and ade-
crease in EC proliferation. This results in a marked
reduction in the length of the small and large bowel
(Fig. 1). Increases in both tumor necrosis factor-
alpha (TNF-) and interferon gamma (INF-)
contribute to the loss of EBF found with TPN
administration. Blockade of TNF signaling with
the use of TNF-receptor knockout mice demon-
strate that the major mediator of mucosal atrophy
is via the TNF-R1 signaling pathway, and without
an intact pathway, mucosal atrophy is significantly
prevented.8 Blockade of IFN- signaling using
INF-–knockout mice has also been shown to be
effective in preventing the loss of EBF.7,9
Microbiome and TPN
Previous studies from our laboratory and others
have shown in a mouse TPN model, in which the
doi: 10.1111/j.1749-6632.2012.06572.x
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Figure 1. (A)Representative imageof harvested intestine from
control (chow fed) andTPNmice.Note the significantly reduced
length of both small and large intestine. (B) Mean length in
centimeters of small and large bowel (colon) from control and
TPN mice. ∗∗P < 0.01.
gut is devoid of all nutrients, a number of signifi-
cant physical and immunologic changes develop in
the intestinal mucosa.9–13 Data from our laboratory
demonstrates that these intestinal changes are in-
timately associated with alterations in the luminal
microbiome.14 Our laboratory identified a major
shift in the microbiome, from a normally benign
composition of mostly Firmacutes, to a predomi-
nantly Gram-negative, Proteobacteria population.
This shift in the microbiome was strongly corre-
lated with a proinflammatory state characterized by
an upregulation in Toll-like receptor (TLR) signal-
ing, including TLR2, TLR4, and TLR9.15 As well,
TPN led to amarked downstream increase inNF-B
activation within the lamina propria, with a resul-
tant increase in inflammatory cytokines INF- and
TNF-, as well as a decreased population of T regu-
latory cells.16 Blockade of this signaling pathway us-
ing myeloid differentiation primary response gene
88 (MyD88) knockout mice demonstrated a signifi-
cant preventionofNF-Bactivation, preventionof a
proinflammatory state, preservation of T regulatory
cell population, and prevention of the loss of EBF.17
Taken together, this suggests that unique strate-
gies to prevent these major microbiome changes,
or block TLR signaling, during TPN administra-
tion may prove to be a strategy to prevent the ad-
verse effects of intestinal atrophy and loss of EBF
(Fig. 2).
TPN results in a loss of local growth factor
production: implications for loss of EBF
The pathophysiology of TPN-driven EC apopto-
sis, decreased EC proliferation, and loss of EBF is
complex. Although conventionally viewed as a me-
diator of cellular death, TNF- signaling has also
been closely linked with cell survival and regulation
of proliferation. In fact, effective epidermal growth
factor (EGF) signaling requires both an intact
TNF-18,19 and ErbB1 receptor pathways. Both EGF
and ErbB1 are markedly diminished with TPN ad-
ministration.8 The combination of a proinflamma-
tory state, with loss of EGF signaling leads to an
imbalance between TNFR1/TNFR2 and EGF sig-
naling. Such a deranged state may well be a major
contributing factor to TPN-associated mucosal at-
rophy and loss of EBF.
Aside from a loss of ErbB ligands, TPN has
also been shown to result in a loss of two other
key mucosal growth factors, keratinocyte growth
factor20–22 and glucagon-like peptide-2 (GLP-2).23
Each of these factors are contributors to mainte-
nance of the intestinal barrier function,24,25 and loss
of these factors seem to be major contributors to
TPN-associated intestinal atrophy.23
TPN-associated loss of EBF26,12 may well re-
sult in increases in bacterial translocation.27–29 The
barrier function of the epithelium is the sum of
several physiological processes, including the syn-
thesis and release of mucus from goblet cells, tran-
scytosis of dimeric secretory IgA, luminally directed
water movement, and the physical integrity of the
epithelial layer itself.30 Breakdown in EBF and im-
munologic derangement can lead to the systemic
dissemination of pathogens that often lead to the
development of multiorgan dysfunction.31 These
findings have been shown in both mouse models
and in humans32 on PN.
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Figure 2. Summary of potential signaling changes with TPN administration. Note loss of nutrients with TPN administration
results in a change in the microbiome (represented by the red dots). This leads to enhanced signaling via Toll-like receptors (TLR)
activating lamina propria lymphoid tissue leading to NF-κB nuclear transcription and a proinflammatory state within the mucosa,
with increases in TNF-α and IFN-γ, and loss of TNF-β and IL-10. These changes lead to a loss of Treg cells and an exacerbation in
the proinflammatory state. In total this leads to a loss of epithelial barrier function.
TPN-associated loss of p-Akt abundance
and loss of tight junctional proteins
Loss of growth factor signaling may lead to a
loss of downstream phosphatidylinositol 3-kinase
(PI3K)/p-Akt signaling. This may have significant
implications, as a critical role of PI3K/Akt signal-
ing in resistance to apoptosis has been reported
in multiple cell types.33,34 Our previous data has
shown that TPN administration led to decreased
p-Akt activity in small bowel ECs, contributing to
the TPN-associated loss of proliferation and in-
creased apoptosis.13 T-cell lymphoma-1 (TCL1) is a
novel Akt-activating peptide (a head-to-tail dimer
of the Akt-binding domain of T cell lymphoma-
1).35 We used this peptide, or an inactive mutant
sequence TCL1G, conjugated to a transactivator of
transcription peptide sequence (TAT), to promote
intracellular uptake. This led to a significant increase
in p-Akt, as well as prevention in both the loss of EC
proliferation and rise in apoptosis with TPN.11
The PI3K/p-Akt signaling may well have impli-
cations on preservation of EBF. PI3K/p-Akt sig-
naling has been reported to affect electrogenic
intestinal transport.36 However, this action may be
partial in that these authors showed that the appli-
cation of the PI3 kinase inhibitor, Wortmannin or
LY294002, did not significantly alter transepithelial
potential difference or resistance. Junctional pro-
teins play a crucial role in the epithelial barrier, and
these can be reflected by the measurement of the
transepithelial potential difference and resistance.
Zonula occludens protein 1 (ZO-1) acts as a func-
tional cross-linker between the E-Cadherin/catenin
complex and actin-based cytoskeleton.37 Other crit-
ical factors that modulate EBF include the fam-
ily of claudins, and these may change significantly
with various disease processes, such as Crohn’s
disease.38,39 In our TPN mice using Western im-
munoblots to measure junctional protein expres-
sion, we found a significant reduction in the
abundance of tight junction proteins ZO-1 and
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occludin, as well as the adhesion junctional pro-
tein E-Cadherin compared to sham (enterally fed)
groups. TCL-1 administration (which drives p-Akt
abundance) partially prevented the loss of ZO-1 and
E-Cadherin expression; however, TCL-1 did not im-
pact the lossof occludin expression.Aswell, transep-
ithelial resistance was not significantly affected in
the TCL-1 TPN group compared to control (non-
TCL1) TPN mice. Thus, the partial prevention of
the loss of p-Akt, was unable to fully prevent the
loss of EBF in this TPN model. Claudins also were
differentially expressed with TPN, including a loss
of claudins 7 and 15.12
As mentioned earlier, our laboratory’s data also
showed that downregulation of E-Cadherin expres-
sion in TPN mice is tightly related to a decrease
in p-Akt activity.13 In addition, we showed an as-
sociation linking the loss of EC proliferation and
increase of EC apoptosis, to a decline in the down-
stream signaling of the p-Akt pathway via GSK3-
and mTOR pathways.11 Interestingly, supplemen-
tation of TPN mice with intravenous glutamine
(GLN) prevented the loss of p-Akt abundance, and
resulted in a recovery of EC proliferation as well
as barrier function.40 (see next section on nutrient
supplementation). These findings are similar to the
McKay group, which recently reported that PI3K
and protein kinase C were mediators of IFN-–
induced increases in epithelial paracellular perme-
ability and the transcytosis of noninvasive, non-
pathogenic Escherichia coli passage across mono-
layers of human gut derived ECs. Although Akt is
an important mediator of many PI3K-dependent
events, this event was Akt independent.41,42 This
may explain our lack of impacting EBF by driving
p-Akt abundance.
Recently, it has been reported that TLR2-induced
tight junction (TJ) modulation strongly interrelates
with promotion of intestinal EC survival through
the PI3K/Akt pathway.43 An ex vivo culturemodel of
primary intestinal epithelial cells showed function-
ally that TLR2 activation promotes cell survival by
inhibiting apoptosis. This effect requires the adap-
tor moleculeMyD88, which contains a p85-binding
site,44 as a putative mechanism to recruit PI3K
downstream on ligand stimulation. TLR2 stimu-
lation efficiently preserves ZO-1–associated barrier
integrity against stress-induced damage, which is
controlled by the PI3K/Akt-pathway via MyD88.
As well, intestinal EC TLR2 functions via PI3K/Akt
to attenuate the MAPK/NF-B–signaling cascade.
Therefore, the complex interactions of an upreg-
ulation of TLR2 in our TPN model may well in-
terrelate with the loss of EC proliferation and EBF.
Because a major signaling mechanism for TLR4 is
via lipopolysaccharide (LPS), much attention has
been focused on how to block this signal. Intestinal
alkaline phosphatase (IAP), which is released by the
brush border of ECs can neutralize LPS andnormal-
ize the intestinal microbiota.45 It will be fascinating
to explore whether nutrient deprivation, with TPN,
can influence IAP production.
Loss of critical nutrients may be a
contributing factor to the development of
EBF loss
With the comprehensive clinical applicationofTPN,
it would seem that clinicians have achieved consen-
sus about the optimal TPN formula. However, even
with the prerequisite of enough caloric intake, there
still are two problems not well handled in the cur-
rent approach to clinical TPN administration: loss
of critical nutrients in the TPN solution and the
lost luminal sensing for nutrients in the gut. Each
of these may contribute to TPN-associated EBF dis-
ruption. These two issues are an emerging research
focus in this field.
To address the first issue, we compared the differ-
ence between TPN versus TPN plus partial (25%)
oral feeding on the intestinal immune system.46
This small amount of enteral feeding significantly
prevented atrophy of the intestinal epithelium and
changes in intraepithelial lymphocytes (IEL) phe-
notypes seen with TPN. As there was a preven-
tion in the upregulation of proinflammatory cy-
tokines (which downregulated normal tight junc-
tion function) with partial enteral feeding, the re-
sults suggest that the major factor responsible for
TPN-associated loss of EBF, bacterial transloca-
tion, and IEL-changes, is the lack of enteral feed-
ing and not the administration of the TPN solution
itself.
Of great interest is the identification of criti-
cal nutrients that could be involved in EBF pro-
tective mechanisms, thereby helping us greatly
improve the formula of TPN administration.
Because GLN has been shown to be an im-
portant amino acid in the modulation of EBF
under various luminal threats, such as en-
dotoxin lipopolysaccharide, we investigated the
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benefits of GLN supplementation on TPN mice.40
Intravenous GLN supplementation significantly
prevented the loss of EBF and mucosal atrophy in
TPN mice. This was shown with an accompanied
decreased intestinal permeability, increased expres-
sion of tight junction proteins (including ZO-1, oc-
cluding, and junctional adhesion molecule-1), as
well as prevention of changes in IEL-derived cy-
tokine profile. It seems that GLN showed this EBF
protective effect in TPNmice by regulating the phe-
notype and function of IEL, potentially via an im-
munomodulatory effect of GLN.40
The GLN studies described earlier were supple-
mented intravenously. It is also possible that the lack
of luminal nutrients with TPN administration not
only leads to some certain nutritional deficiencies,
but may also result in a loss of gut-nutrient sens-
ing. An increasing literature has shown gut taste
receptors (TRs), located throughout the gastroin-
testinal tract, to be involved in gastrointestinal mu-
cosal defense mechanisms.47 It is clear that a variety
of TRs are present throughout the gastrointestinal
tract, and that these arepredominately located in en-
teroendocrine cells and ECs on the luminal side of
themucosa, facing a variety of nutritive and nonnu-
tritive stimuli signals.48 Interestingly, growing evi-
dence has demonstrated that certain sweet receptors
and umami receptors may be under dynamic regu-
lation under differentmetabolic (glucose/glutamate
[GLM]) and luminal stimuli (acid injury/luminal
microbiota); and may have particular relevance in
disease conditions such as diabetes.49 This suggests
that a compensatory mechanism may exist, which
balances nutrient sensing and absorption.50 Fur-
thermore, through activating TRs, taste stimulants
supplementation could enhance the function of the
intestinal immune system.51 Potentially, this stimu-
lation could enhance EBF.
Recently, theumami receptor stimulant,GLMhas
been shown to enhance duodenal mucosal defense
mechanisms through the TRs T1R1/T1R3 andGLM
receptors.52 The Wang group reported that perfu-
sion of L-Glu/IMP (inosine 5′-monophosphate) in-
creased portal venous concentrations of GLP-2 and
GLP-1 and increases duodenal bicarbonate secre-
tion.53 Another recent in vitro study demonstrated
that similar to GLN, GLM treatment reduced the
permeability of IEC monolayers,54 thereby enhanc-
ing EBF. Although there are no publications exam-
ining the action of GLM on EBF during TPN ad-
Figure 3. Summary of the potential mechanisms, which may
be involved in sustainingepithelial barrier functionvia thep-Akt
signaling pathway. Note loss of local growth factors, including
EGF and GLP2, along with respective receptors results in loss of
EBF. Restitution of EBF, along with epithelial cell proliferation
and prevention of apoptosis, occurs in TPN mice with supple-
mentation of glutamine or glutamate, as well as with exogenous
growth factors.
ministration, it is quite possible that stimulation of
these TRsmay act in this way, and thus, restoring gut
nutritional sensing could be a potential strategy to
improve EBF in TPN patients. A summary of these
findings is given in Figure 3.
Conclusions
Although providing the essential macro- and mi-
cronutrients required during a prolonged fast-
ing state, the administration of TPN also leads
to small bowel atrophy, increase in EC apopto-
sis, and increases in proinflammatory mediators.
The resultant effect is a significant loss of EBF,
predominantly via a loss of critical tight junction
proteins.Themechanisms for these actions are com-
plex, but decreases in the p-Akt signaling pathway,
andan increase inproinflammatory cytokines, likely
play important roles. The additional administration
of GLN, the principal energy source for enterocytes,
helps prevent these deleterious effects TPN has on
the small bowel. Conceivably directed enteral stim-
ulates, such as GLM, may also demonstrate intesti-
nal protection via signaling of intestinal TRs. By
continuing to examine the mechanisms of TPN re-
lated complications in the small bowel, and poten-
tial protective modalities, the harmful effects of this
life-prolonging therapy may be eliminated.
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